SOX18 and non-small cell lung carcinoma: Additionally, SOX18 overexpression was related to a poor response to immune checkpoint blockade (ICB) treatment and disease progression post‐treatment (Figure S7D), as well as unfavourable overall survival for NSCLC patients (Figure 3K).